Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy plus adjuvant MESA chemotherapy for stage I-II nasal-type NK/T-cell lymphoma
ChiCTR-ONRC-14005188Phase 2Recruiting
- Sponsor
- Xijing Hospital
- Start
- Apr 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of methotrexate + etoposide + dexamethasone + pegaspargase in Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL), sponsored by Xijing Hospital. Primary endpoint: progression-free survival. Started Apr 2014; status: recruiting.
02
Drugs
methotrexate + etoposide + dexamethasone + pegaspargase
03
Conditions
Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL)
Beyond the preview
Go deeper on ChiCTR-ONRC-14005188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-ONRC-14005188.